![]() |
|
![]() |
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
Sponsors and Collaborators: |
Schering-Plough Integrated Therapeutics Group |
Information provided by: | Schering-Plough |
ClinicalTrials.gov Identifier: | NCT00358527 |
This study will hope to show that by relieving the patient’s nasal symptoms of seasonal allergies using mometasone furoate nasal spray, the patient will obtain a better quality of night-time sleep, which in turn, causes less daytime sleepiness so that he/she can function productively during the day.
Condition | Intervention | Phase |
Seasonal Allergic Rhinitis |
Drug: mometasone furoate nasal spray |
Phase IV |
MedlinePlus related topics: | Allergy Hay Fever Sleep Disorders |
Drug Information available for: | Mometasone furoate Salicylsalicylic acid Sodium salicylate |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Efficacy Study |
Official Title: | A Double-Blind, Placebo-Controlled, Randomized, Parallel-Group Multicenter Study of Mometasone Furoate Nasal Spray on Sleep Disturbances and Daytime Somnolence in Subjects With Symptomatic Seasonal Allergic Rhinitis |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
![]() |
Show 25 Study Locations |
Schering-Plough |
Integrated Therapeutics Group |
Principal Investigator: | Patrick Levy, MD | Centre Hospitalier Universitaire Michallon |
Study ID Numbers: | P04608 |
First Received: | July 31, 2006 |
Last Updated: | January 29, 2007 |
ClinicalTrials.gov Identifier: | NCT00358527 |
Health Authority: | Belgium: Directorate general for the protection of Public health: Medicines; Canada: Health Canada; France: Afssaps - French Health Products Safety Agency; Germany: Federal Institute for Drugs and Medical Devices; Italy: The Italian Medicines Agency; Netherlands: The Central Committee on Research Involving Human Subjects (CCMO); Russia: Pharmacological Committee, Ministry of Health; Spain: Spanish Agency of Medicines; United Kingdom: Medicines and Healthcare Products Regulatory Agency |
|
|
|
|
![]() |